BioPlus Co. Ltd. (099430) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of BioPlus Co. Ltd. KRW 3,936, price KRW 3,285, upside +19.8%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch BioPlus Co. Ltd. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range 3,205 KRW – 8,624 KRW · fair‑value band 2,952 KRW – 4,921 KRW · the 3,285 KRW price screens below the 3,936 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 24, 2026.
Follow BioPlus Co. in your weekly email
Every Wednesday you see whether BioPlus Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names.
Show more
Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus " Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.
Stock analysis
BioPlus Co. Ltd. (099430) currently trades at 3,285 KRW, while our model-based Fair Value estimate is 3,936 KRW, implying the stock looks roughly 16.5% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 10,554 KRW per share, and 10 of the 14 models we run sit above the 3,285 KRW price.
Bear case: the Economic Profit group reads lowest at 1,814 KRW, and 4 of the 14 models stay below the price. Evidence for this calculation is medium.
Scenario range: 2,952 KRW (bear) to 4,921 KRW (bull), the price of 3,285 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
BioPlus Co. Ltd. reported revenue of 90.9B KRW in FY2025 versus 37.4B KRW in FY2021, a compound +24.8%/yr. Reported net income was 15.0B KRW in FY2025, compounding +8.9%/yr from FY2021.
Key figures
Market cap 222B KRW (≈ $163M) · P/S ratio 2.35 · Dividend yield 2.1% · Net margin 16.5% · Return on equity 10.6% · Return on assets (EBIT) 13.3% · Operating margin 21.3% · Revenue (TTM) 94.4B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
The share trades about 53% below its 52-week high and 2% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −13% fair-value upside, at 20%, 099430 screens cheaper than that median.
Fair Value models
Bear 2,952 KRWFair Value 3,936 KRWBull 4,921 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.57/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+36.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+35.1%
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+9.0%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.9%
Dividend (yield on the price)2.1%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.51% → 17%
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is BioPlus Co. Ltd. (099430) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,936 KRW versus a price of 3,285 KRW, about +20% upside (undervalued).
What is the fair value of 099430?
Our model-based fair value for BioPlus Co. Ltd. is 3,936 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 3,285 KRW.
What is the quality score of 099430?
BioPlus Co. Ltd. has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for BioPlus Co. Ltd. (099430)?
Our model-based price target is the fair value of 3,936 KRW (as of Sep 24, 2026) from 14 valuation models. Cautious scenario 2,952 KRW, optimistic scenario 4,921 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the BioPlus Co. Ltd. stock forecast for 2026?
Our models put fair value at 3,936 KRW, about +20% upside versus a price of 3,285 KRW (undervalued). Cautious scenario 2,952 KRW, optimistic scenario 4,921 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of BioPlus Co. Ltd. (099430)?
BioPlus Co. Ltd. reported trailing-twelve-month revenue of about 94.4B KRW (latest available figure, as of Sep 24, 2026).
Does BioPlus Co. Ltd. pay a dividend?
BioPlus Co. Ltd. currently shows a dividend yield of about 2.13% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of BioPlus Co. Ltd. (099430)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For BioPlus Co. Ltd. it is 3,936 KRW per share (as of Sep 24, 2026), against a price of 3,285 KRW. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is BioPlus Co. Ltd. stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 099430 trades below its calculated fair value: price 3,285 KRW, fair value 3,936 KRW, a gap of about +20% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 099430?
No. The price is what the market pays today (3,285 KRW); the fair value is what the company's own numbers justify (3,936 KRW). For BioPlus Co. Ltd. the two are 651.48 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is BioPlus Co. Ltd. worth?
The market values BioPlus Co. Ltd. at about 222B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 3,285 KRW; our models calculate a fair value of 3,936 KRW per share.
What do the bullish and bearish scenarios say about 099430?
Our models span a range for BioPlus Co. Ltd.: cautious scenario 2,952 KRW, base 3,936 KRW, optimistic 4,921 KRW per share (as of Sep 24, 2026, price 3,285 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of BioPlus Co. Ltd. (099430)?
Balance-sheet figures for BioPlus Co. Ltd. (as of Sep 24, 2026): return on equity 10.6%, debt of 0.03 per unit of equity. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is 099430 from its 52-week high?
BioPlus Co. Ltd. trades at 3,285 KRW, about 53% below its 52-week high of 6,932 KRW and 2% above the low of 3,205 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 3,936 KRW is for.
Which stocks are comparable to BioPlus Co. Ltd.?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is BioPlus Co. Ltd. stock attractive at the current price?
The data as of Sep 24, 2026: price 3,285 KRW, calculated fair value 3,936 KRW (+20%), Quality Score 41/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 099430 calculated?
We run BioPlus Co. Ltd. through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,936 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. BioPlus Co. Ltd. currently trades 20 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of BioPlus Co. Ltd. (099430)?
The closing price on Sep 23, 2026 was 3,285 KRW. Our model-based fair value is 3,936 KRW, about +20% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with BioPlus Co. Ltd. right now?
The price sits in the lower half of our model range, the side with the larger margin of safety. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.
Key figures of BioPlus Co. Ltd.
How large is the market capitalisation of BioPlus Co. Ltd. (099430)?
The market capitalisation of BioPlus Co. Ltd. is 222B KRW (≈ $163M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of BioPlus Co. Ltd. (099430)?
The price-to-sales ratio of BioPlus Co. Ltd. is 2.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of BioPlus Co. Ltd. (099430)?
The dividend yield of BioPlus Co. Ltd. is 2.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of BioPlus Co. Ltd. (099430)?
The net margin of BioPlus Co. Ltd. is 16.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of BioPlus Co. Ltd. (099430)?
The return on equity (ROE) of BioPlus Co. Ltd. is 10.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of BioPlus Co. Ltd. (099430)?
On an EBIT basis the return on assets of BioPlus Co. Ltd. is 13.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of BioPlus Co. Ltd. (099430)?
The operating margin of BioPlus Co. Ltd. is 21.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at BioPlus Co. Ltd. (099430)?
Revenue at BioPlus Co. Ltd. is growing +15.4% versus a year earlier (3y avg +17.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at BioPlus Co. Ltd. (099430)?
Earnings per share at BioPlus Co. Ltd. are growing −15.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does BioPlus Co. Ltd. (099430) generate?
The free cash flow of BioPlus Co. Ltd. is −33.2B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does BioPlus Co. Ltd. (099430) carry?
The net debt of BioPlus Co. Ltd. is 38.2B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch BioPlus Co. Ltd. in the live analysis
One click puts BioPlus Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
